Abstract
Background: Hematologic diseases have seriously threatened human health. Although hematopoietic stem cell transplantation (HSCT) is an effective curative option, the complications, especially graft-versus-host disease (GVHD), are a big problem.
Methods: TNF-α pretreatment of hematopoietic stem cells. Apoptosis was detected by flow cytometry, Transwell, and wound healing assays were used to assess cell migration and invasion, E-selectin expression was observed by fluorescence imaging, the levels of NO were measured by a kit, the expression of Ecadherin, MMP2, and MMP9 was detected in cells by qRT-PCR, and western blot was used to analyze the expression of E-cadherin, CXCL12, MCP-1, MCP-3, MMP2, and MMP9.
Results: TNF-α induces a high apoptosis rate of CD3, CD19, and CD133 and a low apoptosis rate of CD34. The level of Fas and TNF-R1 was significantly high than that of TNF-R2. HSCs treated with TNF- α declined the invasion and migration of HUVECs. E-selectin, MMP2 and MMP9 mRNA levels of HUVECs and MMP2, CXCL12, MCP-1, and MCP-3 were decreased after HSCs-TNF-α treatment, while the E-cadherin mRNA and protein level of HUVECs was enhanced with HSCs-TNF-α treatment.
Conclusion: TNF-α pretreated HSCs can lead to reduced levels of migration, adhesion, and chemokines of HUVECs, thereby declining the inflammatory response and GVHD.
[1]
Xu ZL, Huang XJ. Optimizing allogeneic grafts in hematopoietic stem cell transplantation. Stem Cells Transl Med 2021; 10(S2): s41-7.
[http://dx.doi.org/10.1002/sctm.20-0481]
[http://dx.doi.org/10.1002/sctm.20-0481]
[2]
Saha A, Blazar BR. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation. Front Immunol 2022; 13: 1031334.
[http://dx.doi.org/10.3389/fimmu.2022.1031334] [PMID: 36341432]
[http://dx.doi.org/10.3389/fimmu.2022.1031334] [PMID: 36341432]
[3]
Singh V, Kim S, Deol A, Uberti JP, Modi D. Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis. Leuk Lymphoma 2022; 63(4): 855-64.
[http://dx.doi.org/10.1080/10428194.2021.1999438] [PMID: 34866528]
[http://dx.doi.org/10.1080/10428194.2021.1999438] [PMID: 34866528]
[4]
Bu X, Zhong J, Li W, Cai S, Gao Y, Ping B. Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2021; 100(6): 1391-400.
[http://dx.doi.org/10.1007/s00277-021-04486-z] [PMID: 33709198]
[http://dx.doi.org/10.1007/s00277-021-04486-z] [PMID: 33709198]
[5]
Kaito Y, Yui S, Inai K, et al. Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Intern Med 2021; 60(20): 3299-304.
[http://dx.doi.org/10.2169/internalmedicine.6351-20] [PMID: 34657908]
[http://dx.doi.org/10.2169/internalmedicine.6351-20] [PMID: 34657908]
[6]
Crocchiolo R, Ringden O, Bay J-O, et al. Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. Bone Marrow Transplant 2018; 53(2): 213-8.
[http://dx.doi.org/10.1038/bmt.2017.243] [PMID: 29131154]
[http://dx.doi.org/10.1038/bmt.2017.243] [PMID: 29131154]
[7]
Rezzoug F, Huang Y, Tanner MK, et al. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J Immunol 2008; 180(1): 49-57.
[http://dx.doi.org/10.4049/jimmunol.180.1.49] [PMID: 18097003]
[http://dx.doi.org/10.4049/jimmunol.180.1.49] [PMID: 18097003]
[8]
Fan F, Fu L, He G, et al. Infusion of basic fibroblast growth factor ameliorates acute graft versus host disease in mice after haploidentical hematopoietic stem cell transplantation. Immunol Lett 2016; 170: 1-6.
[http://dx.doi.org/10.1016/j.imlet.2015.11.015] [PMID: 26658465]
[http://dx.doi.org/10.1016/j.imlet.2015.11.015] [PMID: 26658465]
[9]
Levy-Barazany H, Shachnai-Pinkas L, Rodionov G, et al. Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance. Bone Marrow Transplant 2020; 55(7): 1305-16.
[http://dx.doi.org/10.1038/s41409-020-0941-2] [PMID: 32433499]
[http://dx.doi.org/10.1038/s41409-020-0941-2] [PMID: 32433499]
[10]
Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, et al. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. Transplantation 2020; 104(12): 2507-15.
[http://dx.doi.org/10.1097/TP.0000000000003383] [PMID: 32639407]
[http://dx.doi.org/10.1097/TP.0000000000003383] [PMID: 32639407]
[11]
Neidemire-Colley L, Robert J, Ackaoui A, Dorrance AM, Guimond M, Ranganathan P. Role of endothelial cells in graft-versus-host disease. Front Immunol 2022; 13: 1033490.
[http://dx.doi.org/10.3389/fimmu.2022.1033490] [PMID: 36505438]
[http://dx.doi.org/10.3389/fimmu.2022.1033490] [PMID: 36505438]
[12]
Takamatsu A, Nakashima Y, Haji S, et al. Circulating endothelial cells and endothelial progenitor cells as potential predictors of acute GVHD after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2022; 109(2): 146-53.
[http://dx.doi.org/10.1111/ejh.13781] [PMID: 35460525]
[http://dx.doi.org/10.1111/ejh.13781] [PMID: 35460525]
[13]
Arias J, Yu J, Varshney M, Inzunza J, Nalvarte I. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions. Stem Cells Transl Med 2021; 10(7): 987-95.
[http://dx.doi.org/10.1002/sctm.20-0459] [PMID: 33634954]
[http://dx.doi.org/10.1002/sctm.20-0459] [PMID: 33634954]
[14]
Hale M, Rawlings DJ, Jackson SW. The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. Curr Opin Immunol 2018; 55: 81-8.
[http://dx.doi.org/10.1016/j.coi.2018.10.008] [PMID: 30390507]
[http://dx.doi.org/10.1016/j.coi.2018.10.008] [PMID: 30390507]
[15]
Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25(1): 139-70.
[http://dx.doi.org/10.1146/annurev.immunol.25.022106.141606] [PMID: 17129175]
[http://dx.doi.org/10.1146/annurev.immunol.25.022106.141606] [PMID: 17129175]
[16]
Mohammad G, Vandooren J, Siddiquei MM, Martens E, Abu El-Asrar AM, Opdenakker G. Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy. Prog Retin Eye Res 2014; 43: 76-91.
[http://dx.doi.org/10.1016/j.preteyeres.2014.07.002] [PMID: 25080402]
[http://dx.doi.org/10.1016/j.preteyeres.2014.07.002] [PMID: 25080402]
[17]
Li Pira G, Di Cecca S, Montanari M, Moretta L, Manca F. Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives. Blood Rev 2016; 30(4): 297-307.
[http://dx.doi.org/10.1016/j.blre.2016.03.001] [PMID: 27066851]
[http://dx.doi.org/10.1016/j.blre.2016.03.001] [PMID: 27066851]
[18]
Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol 2017; 35(36): 4003-11.
[http://dx.doi.org/10.1200/JCO.2017.75.8177] [PMID: 29040031]
[http://dx.doi.org/10.1200/JCO.2017.75.8177] [PMID: 29040031]
[19]
Kanate AS, Craig M, Cumpston A, et al. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2011; 4(4): 149-56.
[http://dx.doi.org/10.5144/1658-3876.2011.149] [PMID: 22198185]
[http://dx.doi.org/10.5144/1658-3876.2011.149] [PMID: 22198185]
[20]
Du W, Cao X. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation. Front Immunol 2018; 9: 2979.
[http://dx.doi.org/10.3389/fimmu.2018.02979] [PMID: 30631325]
[http://dx.doi.org/10.3389/fimmu.2018.02979] [PMID: 30631325]
[21]
Falcon C. AL-Obaidi M, Di Stasi A. Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease. Biomedicines 2017; 5(2): 30.
[http://dx.doi.org/10.3390/biomedicines5020030] [PMID: 28613269]
[http://dx.doi.org/10.3390/biomedicines5020030] [PMID: 28613269]
[22]
Yamashita M, Passegué E. TNF-α Coordinates Hematopoietic Stem Cell Survival and Myeloid Regeneration. Cell Stem Cell 2019; 25(3): 357-372.e7.
[http://dx.doi.org/10.1016/j.stem.2019.05.019] [PMID: 31230859]
[http://dx.doi.org/10.1016/j.stem.2019.05.019] [PMID: 31230859]
[23]
Chopra M, Biehl M, Steinfatt T, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med 2016; 213(9): 1881-900.
[http://dx.doi.org/10.1084/jem.20151563] [PMID: 27526711]
[http://dx.doi.org/10.1084/jem.20151563] [PMID: 27526711]
[24]
Mizrahi K, Yaniv I, Ash S, Stein J, Askenasy N. Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts. Bone Marrow Transplant 2014; 49(5): 640-8.
[http://dx.doi.org/10.1038/bmt.2014.12] [PMID: 24566711]
[http://dx.doi.org/10.1038/bmt.2014.12] [PMID: 24566711]
[25]
Du W, Leigh ND, Bian G, et al. Granzyme B–Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. J Immunol 2015; 195(9): 4514-23.
[http://dx.doi.org/10.4049/jimmunol.1500668] [PMID: 26392464]
[http://dx.doi.org/10.4049/jimmunol.1500668] [PMID: 26392464]
[26]
Moatti A, Debesset A, Pilon C, et al. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation. J Immunother Cancer 2022; 10(4): e003508.
[http://dx.doi.org/10.1136/jitc-2021-003508] [PMID: 35387779]
[http://dx.doi.org/10.1136/jitc-2021-003508] [PMID: 35387779]
[27]
Pearl-Yafe M, Mizrahi K, Stein J, et al. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells 2010; 28(7): 1270-80.
[http://dx.doi.org/10.1002/stem.448] [PMID: 20506490]
[http://dx.doi.org/10.1002/stem.448] [PMID: 20506490]
[28]
Williamson JD, Sadofsky LR, Crooks MG, Greenman J, Hart SP. Bleomycin increases neutrophil adhesion to human vascular endothelial cells independently of upregulation of ICAM-1 and E-selectin. Exp Lung Res 2016; 42(8-10): 397-407.
[http://dx.doi.org/10.1080/01902148.2016.1243742] [PMID: 27797602]
[http://dx.doi.org/10.1080/01902148.2016.1243742] [PMID: 27797602]
[29]
Paulo M, Costa DEFR, Bonaventura D, Lunardi CN, Bendhack LM. Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction. Curr Pharm Des 2020; 26(30): 3748-59.
[http://dx.doi.org/10.2174/1381612826666200519114442] [PMID: 32427079]
[http://dx.doi.org/10.2174/1381612826666200519114442] [PMID: 32427079]
[30]
Yamamoto K, Takagi Y, Ando K, Fukuhara S. Rap1 Small GTPase Regulates Vascular Endothelial-Cadherin-Mediated Endothelial Cell–Cell Junctions and Vascular Permeability. Biol Pharm Bull 2021; 44(10): 1371-9.
[http://dx.doi.org/10.1248/bpb.b21-00504] [PMID: 34602545]
[http://dx.doi.org/10.1248/bpb.b21-00504] [PMID: 34602545]
[31]
Tang Q, Liu Y, Li T, et al. A novel co-drug of aspirin and ursolic acid interrupts adhesion, invasion and migration of cancer cells to vascular endothelium via regulating EMT and EGFR-mediated signaling pathways: multiple targets for cancer metastasis prevention and treatment. Oncotarget 2016; 7(45): 73114-29.
[http://dx.doi.org/10.18632/oncotarget.12232] [PMID: 27683033]
[http://dx.doi.org/10.18632/oncotarget.12232] [PMID: 27683033]
